N/A

All

Market Indices

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Press /

Press /

ASX Indices

Stock Scans

Commodities

Popular Pages

Plans & Portfolios

Home/News/Biotech

Biotech

More Articles

Neuren – Where to from here?

Neuren – Where to from here?

Hashan De Silva·

5 April 2024

Three reporting season scenarios to consider for CSL: Morgan Stanley

Three reporting season scenarios to consider for CSL: Morgan Stanley

1 February 2023

Biotech Arovella to receive Europe patent for its iNKT cell therapy platform

Biotech Arovella to receive Europe patent for its iNKT cell therapy platform

7 November 2022

Paradigm leaps following favourable trial results

Paradigm leaps following favourable trial results

4 October 2022

Mesoblast’s trials to reduce adverse cardiovascular events get hearty response, shares up 7% heading into the close

Mesoblast’s trials to reduce adverse cardiovascular events get hearty response, shares up 7% heading into the close

19 July 2022

Emyria expands MDMA analogue library

Emyria expands MDMA analogue library

Jonathon Davidson·

18 July 2022

Neurotech study finds children with autism benefit from cannabis product

Neurotech study finds children with autism benefit from cannabis product

Jonathon Davidson·

8 July 2022

Echo IQ to present AI heart disease detection tech at high-impact Barcelona conference

Echo IQ to present AI heart disease detection tech at high-impact Barcelona conference

Jonathon Davidson·

7 July 2022

Why the biotech sector might be worth a second look

Why the biotech sector might be worth a second look

5 July 2022

Dimerix to launch diabetes-related disease trial in Australia; FDA interest persists

Dimerix to launch diabetes-related disease trial in Australia; FDA interest persists

Jonathon Davidson·

7 June 2022

Orthocell’s micro collagen bandages aid paralysed muscles

Orthocell’s micro collagen bandages aid paralysed muscles

Jonathon Davidson·

7 June 2022

Latest trial results suggest Incannex's IHL-42X treatment makes for 'higher' quality sleep

Latest trial results suggest Incannex's IHL-42X treatment makes for 'higher' quality sleep

Jonathon Davidson·

3 June 2022

Alterity launches phase 2 trial for rare brain-related disorders

Alterity launches phase 2 trial for rare brain-related disorders

Jonathon Davidson·

2 June 2022

Mesoblast posts $US23.1m 3Q loss: Operational spending slashed

Mesoblast posts $US23.1m 3Q loss: Operational spending slashed

1 June 2022

Cynata Therapeutics jumps as FDA OK’s stem cell rejection treatment

Cynata Therapeutics jumps as FDA OK’s stem cell rejection treatment

Jonathon Davidson·

26 May 2022

PharmAust looks to Eastern Europe for unvaccinated COVID trial participants

PharmAust looks to Eastern Europe for unvaccinated COVID trial participants

Jonathon Davidson·

24 May 2022

Actinogen reassesses its priorities: Clinical programs refocus on cognition

Actinogen reassesses its priorities: Clinical programs refocus on cognition

Company Insights·

4 May 2022

Kazia finalises second phase of novel brain cancer treatment

Kazia finalises second phase of novel brain cancer treatment

Jonathon Davidson·

22 April 2022

Arovella mints manufacturing terms with QIMR Berghofer

Arovella mints manufacturing terms with QIMR Berghofer

Jonathon Davidson·

20 April 2022

Chimeric Therapeutics partners-up to support cell programs

Chimeric Therapeutics partners-up to support cell programs

12 April 2022

Latest News

Technical Analysis

ChartWatch ASX Scans: Evolution Mining, Capricorn Metals, Core Lithium, Metals X, Midas Minerals, Vault Minerals

38 mins ago

Morning Wrap: ASX 200 to fall a fifth day, S&P 500 slips as 30-year yields hit 19-year high

1 hour ago

ASX 200 Live Today - Tuesday, 18th August

LIVE

3 mins ago

Evening Wrap: ASX 200 slides as JB Hi-Fi and NAB results foreshadow consumer wipeout, gold, energy and critical minerals rise

All Categories

Capital Raising

Communication Services

Consumer cyclical

Consumer Discretionary

Consumer Staple

Consumer Staples

Director Transactions

Earnings Highlights

Financial Services

Insights & Opinion

Precious Metals

Reporting Season

Technical Analysis

Weekend Newsletter

Advertisement

ASX INDICES

All ASX Indices

COMMODITIES

All Commodities

INVESTMENT SCANS

Highest Dividend Yield

Broker Consensus

POPULAR PAGES

List of ASX Companies

Upcoming Dividends

Director Transactions

ASX Short Sale Data

ASX Announcements

Australian Dollar

NEWS

Editorial Process

STATS & DOWNLOADS

Market Statistics

RESOURCES

History of the ASX

EDITORS PICKS

How to Buy Shares in Australia

Dividend Yield Basics

The Basics of Franking Credits

Top 10 Investment Movies & Documentaries

OUR NETWORK

Livewire Markets

About Us Careers Privacy FSG Terms Of Use Contact Us

Market Index and its data suppliers accept no responsibility for any claim, loss or damage whatsoever as a result of information on this website or services. The Market Index website is owned by FinTech Equity Pty Ltd (ACN: 637 943 803) AFSL #521588 Factual Information Only: The Market Index website and all content, advertisements and other material contained on our website is factual information only. We are not financial advisers and none of the content on our website should be interpreted as financial advice. Nothing on our website is intended to imply a recommendation or opinion about a financial product or class of financial products. Before you make an investment decision based on any of the information contained on our website, please consult a qualified financial adviser or stockbroker. All content is provided “as is” and not intended for trading purposes.

Copyright © 2026 Market Index